FDA Removes Longtime Director of Over-the-Counter Drugs Office Amid Agency Shakeup

December 4, 2025

WASHINGTON — The U.S. Food and Drug Administration (FDA) has removed Dr. Theresa Michele from her post as Director of the Office of Nonprescription Drugs (ONPD), a move that has sent shockwaves through the pharmaceutical industry and public health community. The decision, announced late Wednesday, comes amid a broader leadership restructuring at the agency and follows a contentious year for the regulation of common over-the-counter (OTC) medications.

According to an internal agency memo reviewed by Health News Daily, Dr. Michele, who has led the office responsible for regulating widely used consumer health products since 2017, is being “transitioned to a new role” within the Center for Drug Evaluation and Research (CDER). No immediate successor has been named, and an interim director is expected to be appointed later this week.

A Sudden Departure

The announcement marks a significant shift for the office that oversees the safety and effectiveness of thousands of nonprescription products, from sunscreens and hand sanitizers to pain relievers and cold medicines. While the FDA declined to comment on personnel matters, sources close to the agency suggest the move is part of a larger realignment of the FDA’s priorities under the current administration’s new health directives.

“This is a major disruption in the continuity of OTC regulation,” said Dr. Sarah Gunden, a former FDA senior medical officer and current health policy analyst at the height of the transition. “Dr. Michele was a central figure in modernizing the OTC monograph system. Her sudden removal suggests a pivot in how the agency intends to manage nonprescription drugs moving forward.”

The Phenylephrine Fallout

The leadership change occurs in the wake of the high-profile controversy surrounding oral phenylephrine, a popular ingredient found in hundreds of cold and flu decongestants. Under Dr. Michele’s leadership, the ONPD conducted a comprehensive review that culminated in a late 2024 proposal to remove the ingredient from the market after an advisory committee unanimously declared it ineffective at standard dosages.

“Dr. Michele was the face of the agency’s data-driven decision to challenge the status quo on phenylephrine,” noted Dr. Marcus Thorne, a clinical pharmacologist at Johns Hopkins University who was not involved in the FDA’s internal review. “Her team stood firm on the science despite significant pushback from industry stakeholders who feared billions in lost revenue. It raises the question: Is this move a response to that aggressive regulatory stance?”

The proposal to ban oral phenylephrine had drawn sharp criticism from trade associations, who argued that removing the ingredient would limit consumer choice and cause unnecessary confusion during respiratory virus seasons.

Broader Implications for Public Health

The Office of Nonprescription Drugs plays a critical role in the daily lives of Americans. Unlike prescription drugs, which require a doctor’s authorization, OTC medicines are the first line of defense for minor ailments for millions of families.

Experts warn that instability in the ONPD’s leadership could delay critical initiatives, including:

• The “OTC Switch” Program: Efforts to make more prescription drugs (such as oral contraceptives and chronic disease medications) available over the counter.

• Sunscreen Safety: Long-awaited updates to safety standards for sunscreen ingredients.

• Modernization: Implementing the reforms from the CARES Act, which was designed to speed up the sluggish OTC review process.

“The public relies on this office to ensure that the bottle of syrup they buy at the grocery store works and is safe,” said Jennifer Nuzzo, a public health researcher. “If regulatory oversight is weakened or politicized, consumer confidence in these everyday products could erode.”

Industry Reaction

The pharmaceutical industry has reacted cautiously to the news. The Consumer Healthcare Products Association (CHPA), which represents manufacturers of OTC medicines, issued a brief statement acknowledging Dr. Michele’s service but emphasizing their commitment to working with the new leadership.

“We look forward to a constructive dialogue with the ONPD’s incoming leadership to ensure Americans continue to have access to safe, effective, and innovative self-care products,” the statement read.

Market analysts, however, interpret the move as a potential signal of deregulation. “Investors may see this as a sign that the FDA will take a lighter touch with legacy OTC products that have been on the market for decades,” said financial analyst Greg Aleston.

What This Means for Consumers

For now, products on store shelves remain unaffected. However, the change in leadership could slow down the finalization of the ban on oral phenylephrine, meaning consumers might continue to see products the FDA previously deemed “ineffective” on shelves for longer than expected.

“Consumers should remain vigilant,” advised Dr. Thorne. “Regardless of who sits in the director’s chair, the science hasn’t changed. Read labels, talk to your pharmacists, and choose products with ingredients proven to work.”

As the FDA navigates this transition, the healthcare community waits to see whether Dr. Michele’s departure signals a new era of deregulation or simply a changing of the guard in an agency under intense scrutiny.

Medical Disclaimer:

This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References

1. Reuters. (2025, December 3). US FDA removes longtime director of over-the-counter drugs office. Thomson Reuters.